23 Academy-ro
Yeonsu-gu
Incheon
South Korea
82 3 2850 5000
https://www.celltrion.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Hyong-Gi Kim | CEO & Internal Director | N/D | N/D | 1965 |
Mr. Woo-Sung Kee | CEO & Internal Director | N/D | N/D | 1961 |
Jin-seok Seo | Co-CEO & Inside Co-Chairman of the Board | N/D | N/D | N/D |
Mr. Stephen Yeum | Founder | N/D | N/D | N/D |
Mr. Min-Cheol Shin | Director of Finance | N/D | N/D | 1971 |
Mr. Ji-Hoon Choi | Director of Legal Affairs | N/D | N/D | 1971 |
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 3 clinical trial; CT-P17 for the treatment of autoimmune diseases which is in phase 3 clinical trial; CT-P16 for the treatment of non-small cell lung cancer and colon cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 3 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P47 for the treatment of rheumatoid arthritis, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. The company was founded in 2002 and is headquartered in Incheon, South Korea.
L'ISS Governance QualityScore di Celltrion, Inc. al 1 maggio 2024 è 3. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 4; diritti degli azionisti: 4; retribuzione: 1.